University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco's Flavored Tobacco Law Rooted in Years of Advocacy Work

San Francisco's Flavored Tobacco Law Rooted in Years of Advocacy Work

July 12, 2017

Studies conducted separately by the U.S. Food and Drug Administration and its Tobacco Products Scientific Advisory Committee found that the removal of menthol from the marketplace would benefit public health.

Big-Data Analysis Points Toward New Drug Discovery Method

Big-Data Analysis Points Toward New Drug Discovery Method

July 12, 2017

A research team led by scientists at UC San Francisco has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs.

Google Searches Could Help Track Cancer Incidence, Mortality

Google Searches Could Help Track Cancer Incidence, Mortality

July 7, 2017

America’s most popular search engine could soon be assisting with cancer research.

UCSF Cancer Researcher Leads Team to Win First Ever AI Genomics Hackathon

UCSF Cancer Researcher Leads Team to Win First Ever AI Genomics Hackathon

July 7, 2017

A UC San Francisco cancer researcher has led a team of data scientists and engineers to win a first-of-its-kind Artificial Intelligence (AI) Genomics Hackathon competition.

Incidents of Smoking Increase Dramatically in Youth-focused, PG-13 Films

Incidents of Smoking Increase Dramatically in Youth-focused, PG-13 Films

July 6, 2017

Youth-rated films, which are designed and marketed as kid-friendly, continue to fill the movie screen with tobacco imagery, according to a new report from UC San Francisco, the U.S. Centers for Disease Control and Prevention, and other entities.

Test Identifies Breast Cancer Patients with Lowest Risk of Death

Test Identifies Breast Cancer Patients with Lowest Risk of Death

June 29, 2017

A molecular test can pinpoint which patients will have a very low risk of death from breast cancer even 20 years after diagnosis and tumor removal, according to a new clinical study led by UC San Francisco in collaboration with colleagues in Sweden. As a result, “ultralow” risk patients could be treated less aggressively and overtreatment avoided, leading to fewer toxic effects.